Healixia: Towards a global implementation of eConsent in clinical trials

Datum: 16 March 2021

Tijd: 1:00 PM to 2:00 PM

Lou Guffroy will present and discuss the current literature, the development of a prospective questionnaire on eConsent experiences sent to +3000 clinical research experts in Belgium, The Netherlands and Luxembourg. The results and recommendations of the survey, addressed to 5 different stakeholders, next to expert interviews, will conclude this presentation.

Continue Reading

Healixia: Impact of Covid-19 on clinical trial execution

Datum: 8 December 2020

Tijd: 13.00 - 14.00 uur

Locatie: Webinar

Since the start of the COVID-19 outbreak clinical research has been impacted around the globe. Apart from the difficulties, the epidemic has also been a catalyst for positive change enabling faster uptake of new processes and technologies. This webinar aims to provide you with a unique perspective, bringing together first hand experiences from site and sponsor about opportunities and challenges.

Continue Reading

Healixia’s journey – Let’s connect

Startdatum: 14 October 2020

Einddatum: 17 November 2020

Locatie: Multiple webinars

10 November - Pioneering malaria challenge trials in Belgium: from theory to practice in a Phase I unit

13 November - Advanced therapies: the demise of alchemy and rise of pharmacology

16 November - “The scientific approach to a virus epidemic”

17 November - Online closing event: we look back on the past webinars and give the floor to a leading speaker in the field of healthcare.

TBC - "Collaboration between paediatric network sites in Belgium"
TBC - "Value based healthcare"

Continue Reading

Healixia: Workshop: Pioneering malaria challenge trials in Belgium: from theory to practice in a Phase I unit

Datum: 10 November 2020

Tijd: 13.15 - 18.00 uur

Locatie: Online

Human Challenge Trials (HCT) or Human Infection Models (HIM) are an extremely effective way of validating treatment efficacy using real-world symptomology studies. The challenge of infectious agents with vaccine (or drug) in vivo offers early access to mode of action (MOA) and proof of concept (POC) data prior to designing later, larger phase field trials. The last two decades have seen a surge in antimalarial drug development with product development partnerships taking a leading role. The development of resistance to the past and present anti-malarial drugs highlights the need for continued research to stay one step ahead. New drugs are needed, particularly those with new mechanisms of action. Malaria Volunteer Infection Studies (VIS) serve as a valuable tool in antimalarial drug development. Both for prophylactic and curative treatment, models have been developed in clinical trials by injection of infected red blood cells or direct inoculation with malaria sporozoites. Pioneer trials have already been performed in different countries such as Australia and the Netherlands. Last year, the first malaria-VIS trial has been performed in Belgium, aiming to investigate a prophylactic treatment. A second VIS-trial testing a curative treatment model will start in March 2020. This workshop offers unique insights about Belgium’s pioneer malaria-VIS trials from the scientific community, the sponsor’s and the investigator’s perspective.

Continue Reading